222 related articles for article (PubMed ID: 20505515)
1. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma.
Hessheimer AJ; Forner A; Varela M; Bruix J
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1239-44. PubMed ID: 20505515
[TBL] [Abstract][Full Text] [Related]
2. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
[TBL] [Abstract][Full Text] [Related]
3. Obesity, fatty liver and liver cancer.
Qian Y; Fan JG
Hepatobiliary Pancreat Dis Int; 2005 May; 4(2):173-7. PubMed ID: 15908310
[TBL] [Abstract][Full Text] [Related]
4. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.
Marrero JA; Fontana RJ; Su GL; Conjeevaram HS; Emick DM; Lok AS
Hepatology; 2002 Dec; 36(6):1349-54. PubMed ID: 12447858
[TBL] [Abstract][Full Text] [Related]
5. Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease.
Rubinstein E; Lavine JE; Schwimmer JB
Semin Liver Dis; 2008 Nov; 28(4):380-5. PubMed ID: 18956294
[TBL] [Abstract][Full Text] [Related]
6. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.
Lu SN; Wang JH; Liu SL; Hung CH; Chen CH; Tung HD; Chen TM; Huang WS; Lee CM; Chen CC; Changchien CS
Cancer; 2006 Nov; 107(9):2212-22. PubMed ID: 17019738
[TBL] [Abstract][Full Text] [Related]
7. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?
Nair S; Mason A; Eason J; Loss G; Perrillo RP
Hepatology; 2002 Jul; 36(1):150-5. PubMed ID: 12085359
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic steatohepatitis.
Brunt EM
Semin Liver Dis; 2004 Feb; 24(1):3-20. PubMed ID: 15085483
[TBL] [Abstract][Full Text] [Related]
9. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
Caldwell SH; Oelsner DH; Iezzoni JC; Hespenheide EE; Battle EH; Driscoll CJ
Hepatology; 1999 Mar; 29(3):664-9. PubMed ID: 10051466
[TBL] [Abstract][Full Text] [Related]
10. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis.
Serfaty L; Lemoine M
Diabetes Metab; 2008 Dec; 34(6 Pt 2):634-7. PubMed ID: 19195623
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics of patients with cryptogenic liver cirrhosis in Okinawa, Japan.
Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kobashigawa K; Kinjo F; Saito A
Hepatogastroenterology; 2003; 50(54):2005-8. PubMed ID: 14696453
[TBL] [Abstract][Full Text] [Related]
12. Obesity and diabetes as a risk factor for hepatocellular carcinoma.
Regimbeau JM; Colombat M; Mognol P; Durand F; Abdalla E; Degott C; Degos F; Farges O; Belghiti J
Liver Transpl; 2004 Feb; 10(2 Suppl 1):S69-73. PubMed ID: 14762843
[TBL] [Abstract][Full Text] [Related]
13. Diabetes and hepatocellular carcinoma: what role does diabetes have in the presence of other known risk factors?
Davila JA
Am J Gastroenterol; 2010 Mar; 105(3):632-4. PubMed ID: 20203644
[TBL] [Abstract][Full Text] [Related]
14. The epidemiology of nonalcoholic fatty liver disease in adults.
Clark JM
J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768
[TBL] [Abstract][Full Text] [Related]
15. Obesity as a risk factor for hepatocellular carcinoma in a noncirrhotic patient.
Gonzalez L; Blanc JF; Sa Cunha A; Rullier A; Saric J; Le Bail B; Balabaud C; Bioulac-Sage P
Semin Liver Dis; 2004 Nov; 24(4):415-9. PubMed ID: 15605309
[No Abstract] [Full Text] [Related]
16. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
17. Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus.
Konishi I; Hiasa Y; Shigematsu S; Hirooka M; Furukawa S; Abe M; Matsuura B; Michitaka K; Horiike N; Onji M
Liver Int; 2009 Sep; 29(8):1194-201. PubMed ID: 19422477
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants.
Pais R; Lebray P; Rousseau G; Charlotte F; Esselma G; Savier E; Thabut D; Rudler M; Eyraud D; Vezinet C; Siksik JM; Vaillant JC; Hannoun L; Poynard T; Ratziu V
Clin Gastroenterol Hepatol; 2015 May; 13(5):992-9.e2. PubMed ID: 25459558
[TBL] [Abstract][Full Text] [Related]
19. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States.
Afzali A; Berry K; Ioannou GN
Liver Transpl; 2012 Jan; 18(1):29-37. PubMed ID: 21932374
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan.
Okanoue T; Umemura A; Yasui K; Itoh Y
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():153-62. PubMed ID: 21199527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
